Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

Analysts estimate that Nyxoah will report an earnings per share (EPS) of $-0.63. Nyxoah bulls will hope to hear the company ...

Nyxoah SA (NASDAQ:NYXH) is set to release its Q2 2025 earnings on Aug 18, 2025. The consensus estimate for Q2 2025 revenue is ...

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business UpdatesAnnounced on August 8, 2025, that the U.S.

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design ...

Nyxoah to Present at the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – May 28, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the ...

Nyxoah (NASDAQ:NYXH – Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Nyxoah to post earnings of ($0.49 ...